Diethyl fumarate exhibits potent activity against differentially culturable Mycobacterium tuberculosis persisters.
5 affiliations
- 1Leicester Tuberculosis Research Group, Infection and Microbiology Division, School of Biological and Biomedical Sciences, University of Leicester, Leicester, United Kingdom.
- 2Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
- 3Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia.
- 4Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom.
- 5Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains the leading cause of death from a single infectious agent. During infection, Mtb forms drug-tolerant persisters, including differentially culturable (DC) cells that fail to grow on solid media and contribute to prolonged TB treatment and disease relapse. DC Mtb formation is driven by host inflammatory responses, particularly nitric oxide (NO), suggesting that anti-inflammatory agents may limit persister generation. Here, we developed a workflow to evaluate the activity of drug candidates against DC Mtb persisters. This approach was validated using dimethyl fumarate (DMF) derivatives, as DMF has previously been shown to eradicate DC Mtb but is limited by instability and poor solubility. We assessed DMF and nine DMF derivatives for antimycobacterial activity. The workflow included antimicrobial susceptibility testing against Mycobacterium tuberculosis (Mtb) and Mycobacterium abscessus (Mabs), followed by cytotoxicity evaluation and measurement of NO release in lipopolysaccharide (LPS)-stimulated macrophages. Selected DMF derivatives were further tested against DC Mtb persisters generated in vitro using a NO donor as well as persisters recovered from interferon γ-stimulated macrophages. DMF and diethyl fumarate (DEF) inhibited Mtb growth, while ethyl-3-benzoylacrylate (EBL) and methyl-trans-4-oxo-2-pentenoate (MTOP) exhibited bactericidal activity against both Mtb and Mabs. DEF effectively eliminated DC Mtb in infected macrophages, with activity comparable to DMF. This anti-DC Mtb persister effect was associated with reduced NO production, highlighting the importance of anti-inflammatory activity in targeting DC Mtb persisters. DMF and its more soluble and stable derivative DEF represent promising candidates for the development of therapies targeting DC Mtb persisters. Their dual anti-inflammatory and anti-mycobacterial properties support their potential as a novel therapeutic strategy against persistent tuberculosis infections.
Related
- Identification and serological characterization of MtbAg1073, a conserved Mycobacterium tuberculosis complex antigen recognized in active tuberculosis
- Commentary: A proteome-wide atlas of humoral immunity to Mycobacterium tuberculosis across the spectrum of disease
- Mycobacterium tuberculosis Rv2074 is a coenzyme F420-dependent mycobilin reductase
- Case Report: Analysis of antimicrobial therapy and pharmaceutical care of mixed Aspergillus and Mycobacterium tuberculosis infection following renal transplantation: a case study
- Availability of genotypic and phenotypic drug susceptibility testing for Mycobacterium tuberculosis in WHO European Region
BibTeX
@article{herbert2026diethyl,
title = {{Diethyl fumarate exhibits potent activity against differentially culturable Mycobacterium tuberculosis persisters.}},
author = {Amelie J Herbert and Obolbek Turapov and Fraser MacDonald and Irawaty Djaharuddin and Muhammad Nasrum Massi and Douglas B Kell and Vadim A Makarov and Galina V Mukamolova},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1901638},
url = {https://europepmc.org/article/MED/42922847},
note = {CC BY},
}
RIS
TY - JOUR
TI - Diethyl fumarate exhibits potent activity against differentially culturable Mycobacterium tuberculosis persisters.
AU - Amelie J Herbert
AU - Obolbek Turapov
AU - Fraser MacDonald
AU - Irawaty Djaharuddin
AU - Muhammad Nasrum Massi
AU - Douglas B Kell
AU - Vadim A Makarov
AU - Galina V Mukamolova
PY - 2026
DA - 2026/10/08
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1901638
UR - https://europepmc.org/article/MED/42922847
AB - Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains the leading cause of death from a single infectious agent. During infection, Mtb forms drug-tolerant persisters, including differentially culturable (DC) cells that fail to grow on solid media and contribute to prolonged TB treatment and disease relapse. DC Mtb formation is driven by host inflammatory responses, particularly nitric oxide (NO), suggesting that anti-inflammatory agents may limit persister generation. Here, we developed a workflow to evaluate the activity of drug candidates against DC Mtb persisters. This approach was validated using dimethyl fumarate (DMF) derivatives, as DMF has previously been shown to eradicate DC Mtb but is limited by instability and poor solubility. We assessed DMF and nine DMF derivatives for antimycobacterial activity. The workflow included antimicrobial susceptibility testing against Mycobacterium tuberculosis (Mtb) and Mycobacterium abscessus (Mabs), followed by cytotoxicity evaluation and measurement of NO release in lipopolysaccharide (LPS)-stimulated macrophages. Selected DMF derivatives were further tested against DC Mtb persisters generated in vitro using a NO donor as well as persisters recovered from interferon γ-stimulated macrophages. DMF and diethyl fumarate (DEF) inhibited Mtb growth, while ethyl-3-benzoylacrylate (EBL) and methyl-trans-4-oxo-2-pentenoate (MTOP) exhibited bactericidal activity against both Mtb and Mabs. DEF effectively eliminated DC Mtb in infected macrophages, with activity comparable to DMF. This anti-DC Mtb persister effect was associated with reduced NO production, highlighting the importance of anti-inflammatory activity in targeting DC Mtb persisters. DMF and its more soluble and stable derivative DEF represent promising candidates for the development of therapies targeting DC Mtb persisters. Their dual anti-inflammatory and anti-mycobacterial properties support their potential as a novel therapeutic strategy against persistent tuberculosis infections.
SN - 2235-2988
ER -